Last reviewed 2026-04-20 · How we verify

medical

Medical () is a marketed product by Assiut University for occasional constipation relief, currently holding an unspecified market position. The key strength lies in its patent protection, which extends until 2028, providing a barrier to generic competition. The primary risk is the lack of detailed revenue data and key trial results, which may limit investor confidence and market valuation.

At a glance

Approved indications

• Occasional constipation relief

Common side effects

No common side effects on file.

Key clinical trials

• A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
• Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
• Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
• Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors (PHASE1)
• Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (PHASE2)
• Conservative Treatment of Trigger Finger (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.